Study of E7389 for Advanced or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Eribulin Mesylate
Sponsor: Eisai Co., Ltd.